Diego Rincón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Diego Rincón has a total of 498 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Bañares
Department of Digestive Diseases, Instituto de Investigación Sanitaria, Hospital General Universitario Gregorio Marañón, Universidad Complutense Madrid, 28007 Madrid, Spain
48 shared publications - Cristina Ripoll
Department of Internal Medicine IV, Jena University Hospital, Jena, Germany
17 shared publications Magdalena Salcedo
14 shared publicationsGerardo Clemente
Unidad de Hepatología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
13 shared publicationsAna Matilla
Medicina–Ap. Digestivo Hospital General Universitario Gregorio Marañón – CIBERehd – IiSGM. Madrid Spain
8 shared publicationsOreste Lo Iacono
Servicio de Gastroenterología, Hospital del Tajo, Aranjuez, Madrid, Spain
8 shared publications
Latest Publications
- Open Access
- 13 November 2025
- Published by Wiley in Liver International
- Vol. 45 (12) , e70429
Clinical Perspectives on Long‐Term Albumin Therapy in Decompensated Cirrhosis: A Nationwide Delphi Survey in Spain—The ALBA Study
Background and Aims: Albumin is well established for some acute indications in decompensated cirrhosis, but its long‐term use remains controversial. The ALBA study explored expert clinical perspectives, barriers, and current practices regarding long‐term albumin therapy in Spain. Methods: A two‐round national Delphi study was conducted among 47 hepatology experts from Spanish hospitals with broad geographic coverage. The survey included 40 Delphi statements and 14 items on opinion, attitude, and behaviour across five domains. Consensus was defined as Tastle's coefficient ≥ 0.8. Items with moderate consensus (0.7–0.79) and < 70% agreement, or < 0.7, were re‐evaluated in round two. Results: Long‐term albumin was reportedly used in 25.5% of centers. However, panellists broadly supported its potential benefit in preventing ascites‐related complications and endorsed its use regardless of transplant eligibility. It was prioritised for patients with difficult‐to‐control ascites (89.3%) and renal impairment (55.2%), though benefits were perceived as lower in late‐stage disease. Day hospitals were seen as the most appropriate setting, despite strain. Main barriers included evidentiary limitations, institutional logistics, and pharmacy restrictions. Therapy was viewed as overall safe, with dose‐dependent cardiac risk, and considered cost‐effective. Strong support was expressed for a national registry to guide implementation. Conclusions: Panellists considered long‐term albumin administration to be clinically beneficial and prioritised its use for patients with advanced‐stage disease, regardless of transplant candidacy. However, integration into routine practice remains limited due to a lack of robust supporting evidence, along with institutional and logistical barriers. A national registry and targeted strategies to optimise use and resource allocation were endorsed.
- 13 November 2025
- Published by Wiley in Liver International
- Vol. 45 (12) , e70429
Open AccessClinical Perspectives on Long‐Term Albumin Therapy in Decompensated Cirrhosis: A Nationwide Delphi Survey in Spain—The ALBA Study
Background and Aims: Albumin is well established for some acute indications in decompensated cirrhosis, but its long‐term use remains controversial. The ALBA study explored expert clinical perspectives, barriers, and current practices regarding long‐term albumin therapy in Spain. Methods: A two‐round national Delphi study was conducted among 47 hepatology experts from Spanish hospitals with broad geographic coverage. The survey included 40 Delphi statements and 14 items on opinion, attitude, and behaviour across five domains. Consensus was defined as Tastle's coefficient ≥ 0.8. Items with moderate consensus (0.7–0.79) and < 70% agreement, or < 0.7, were re‐evaluated in round two. Results: Long‐term albumin was reportedly used in 25.5% of centers. However, panellists broadly supported its potential benefit in preventing ascites‐related complications and endorsed its use regardless of transplant eligibility. It was prioritised for patients with difficult‐to‐control ascites (89.3%) and renal impairment (55.2%), though benefits were perceived as lower in late‐stage disease. Day hospitals were seen as the most appropriate setting, despite strain. Main barriers included evidentiary limitations, institutional logistics, and pharmacy restrictions. Therapy was viewed as overall safe, with dose‐dependent cardiac risk, and considered cost‐effective. Strong support was expressed for a national registry to guide implementation. Conclusions: Panellists considered long‐term albumin administration to be clinically beneficial and prioritised its use for patients with advanced‐stage disease, regardless of transplant candidacy. However, integration into routine practice remains limited due to a lack of robust supporting evidence, along with institutional and logistical barriers. A national registry and targeted strategies to optimise use and resource allocation were endorsed.
- 5 April 2023
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (2) , 199-205
Hepatic hemodynamic study: More than just HVPG measurement
- 5 April 2023
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 47 (2) , 199-205
Hepatic hemodynamic study: More than just HVPG measurement
- Open Access
- 5 December 2017
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3) , 823-825
Fungaemia caused by rare yeasts: incidence, clinical characteristics and outcome over 10 years
- 5 December 2017
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 73 (3) , 823-825
Open AccessFungaemia caused by rare yeasts: incidence, clinical characteristics and outcome over 10 years
- 1 June 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (6) , 945-949.e1
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
- 1 June 2017
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 15 (6) , 945-949.e1
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
- 1 June 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (6) , 1138-1148
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
- 1 June 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (6) , 1138-1148
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
- 2 May 2017
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 22, 265-275
Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients
- 2 May 2017
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 22, 265-275
Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients
- Open Access
- 1 March 2017
- Published by Elsevier in Nefrología
- Vol. 37 (2) , 158-163
Eficacia de los antivirales de acción directa en la infección por el virus de la hepatitis C en pacientes en hemodiálisis
- 1 March 2017
- Published by Elsevier in Nefrología
- Vol. 37 (2) , 158-163
Open AccessEficacia de los antivirales de acción directa en la infección por el virus de la hepatitis C en pacientes en hemodiálisis
- Open Access
- 13 February 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (6) , 2019-2030
Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis
An accurate evaluation of cardiac function in patients with cirrhosis remains a challenge. We used robust echocardiographic indices to characterize left ventricular (LV) systolic function and its relationship to activation of the sympathetic nervous system and inflammation in 59 patients with cirrhosis and 59 age‐matched controls. Additionally, in 11 patients we withdrew beta‐blockers and diuretics and used phenylephrine and albumin infusion to evaluate the response to acute afterload and preload changes (interventional substudy). Measures of systolic LV function such as the ejection intraventricular pressure difference (EIVPD) and the systolic strain rate were higher in patients with cirrhosis than in controls (median [1st‐3rd quartile], 4.0 [3.1‐5.1] versus 2.9 [2.4‐3.6] mm Hg and –1.3 [–1.6 to –1.1] versus –1.2 [–1.6 to –1.1)] s–1, respectively; P < 0.05 for both). EIVPD was related to the severity of liver disease (Model for End‐Stage Liver Disease, rho = 0.45, P < 0.001), the degree of sympathetic nervous system activation (noradrenaline, rho = 0.26, P = 0.05; heart rate variability, rho = –0.43, P = 0.003), and treatment with beta‐blockers (P = 0.001). In the interventional substudy, EIVPD was higher in patients with ascites (6.5 [5.4‐8.5] versus 4.0 [3.9‐5.1] mm Hg, P = 0.045). The decrease in EIVPD induced by phenylephrine was inversely related to baseline systolic function (P < 0.05) and associated with markers of systemic vasodilatation (nitric oxide, rho = –0.66, P = 0.06; diastolic blood pressure, rho = 0.68, P = 0.04) and inflammation (interleukin‐1beta, rho = –0.80, P = 0.009). Conclusion: LV systolic function is enhanced in cirrhosis due to augmented adrenergic tone and modulated by treatment with beta‐blockers; acute afterload stress induces a deeper impairment of systolic function in patients with more advanced degrees of vasodilatation and inflammation; these changes in LV function related to cirrhosis can be assessed using robust echocardiographic methods. (Hepatology 2017;65:2019‐2030).
- 13 February 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (6) , 2019-2030
Open AccessLeft ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis
An accurate evaluation of cardiac function in patients with cirrhosis remains a challenge. We used robust echocardiographic indices to characterize left ventricular (LV) systolic function and its relationship to activation of the sympathetic nervous system and inflammation in 59 patients with cirrhosis and 59 age‐matched controls. Additionally, in 11 patients we withdrew beta‐blockers and diuretics and used phenylephrine and albumin infusion to evaluate the response to acute afterload and preload changes (interventional substudy). Measures of systolic LV function such as the ejection intraventricular pressure difference (EIVPD) and the systolic strain rate were higher in patients with cirrhosis than in controls (median [1st‐3rd quartile], 4.0 [3.1‐5.1] versus 2.9 [2.4‐3.6] mm Hg and –1.3 [–1.6 to –1.1] versus –1.2 [–1.6 to –1.1)] s–1, respectively; P < 0.05 for both). EIVPD was related to the severity of liver disease (Model for End‐Stage Liver Disease, rho = 0.45, P < 0.001), the degree of sympathetic nervous system activation (noradrenaline, rho = 0.26, P = 0.05; heart rate variability, rho = –0.43, P = 0.003), and treatment with beta‐blockers (P = 0.001). In the interventional substudy, EIVPD was higher in patients with ascites (6.5 [5.4‐8.5] versus 4.0 [3.9‐5.1] mm Hg, P = 0.045). The decrease in EIVPD induced by phenylephrine was inversely related to baseline systolic function (P < 0.05) and associated with markers of systemic vasodilatation (nitric oxide, rho = –0.66, P = 0.06; diastolic blood pressure, rho = 0.68, P = 0.04) and inflammation (interleukin‐1beta, rho = –0.80, P = 0.009). Conclusion: LV systolic function is enhanced in cirrhosis due to augmented adrenergic tone and modulated by treatment with beta‐blockers; acute afterload stress induces a deeper impairment of systolic function in patients with more advanced degrees of vasodilatation and inflammation; these changes in LV function related to cirrhosis can be assessed using robust echocardiographic methods. (Hepatology 2017;65:2019‐2030).
- 15 December 2016
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 24 (6) , 464-471
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience
Summary: Limited data are available on direct‐acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15‐29 mL/min/1.73m2) or 5 (eGFR2 or requiring dialysis) and HCV infection by genotypes 1 and 4 between April 2015 and October 2015 in nine Spanish centres. Sustained virological response at 12 weeks (SVR12) was assessed, and clinical and laboratory data, fibrosis stage, adverse events and pharmacological interactions were reported. Forty‐six patients were included: 10 (21.7%) had CKD stage 4 and 36 (78.2%) CKD stage 5. Seventeen (36.9%) had cirrhosis. SVR12 rate in the intention‐to‐treat population was 95.7%. Twenty‐one (45.6%) received RBV, which was discontinued in two (9.5%) patients. Anaemia (haemoglobin P=.246). Renal function remained stable during antiviral therapy. Nine patients (19.5%) experienced serious adverse events unrelated to antiviral therapy. Concomitant medication was discontinued or modified in 41.3% of patients. In conclusion, the effectiveness of OBV/PTV/r±DSV±RBV in patients with CKD 4‐5 was similar to that observed in those with normal renal function and was not associated with severe adverse events.
- 15 December 2016
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 24 (6) , 464-471
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience
Summary: Limited data are available on direct‐acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15‐29 mL/min/1.73m2) or 5 (eGFR2 or requiring dialysis) and HCV infection by genotypes 1 and 4 between April 2015 and October 2015 in nine Spanish centres. Sustained virological response at 12 weeks (SVR12) was assessed, and clinical and laboratory data, fibrosis stage, adverse events and pharmacological interactions were reported. Forty‐six patients were included: 10 (21.7%) had CKD stage 4 and 36 (78.2%) CKD stage 5. Seventeen (36.9%) had cirrhosis. SVR12 rate in the intention‐to‐treat population was 95.7%. Twenty‐one (45.6%) received RBV, which was discontinued in two (9.5%) patients. Anaemia (haemoglobin P=.246). Renal function remained stable during antiviral therapy. Nine patients (19.5%) experienced serious adverse events unrelated to antiviral therapy. Concomitant medication was discontinued or modified in 41.3% of patients. In conclusion, the effectiveness of OBV/PTV/r±DSV±RBV in patients with CKD 4‐5 was similar to that observed in those with normal renal function and was not associated with severe adverse events.